Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

607
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
607
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

574
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
574
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

817
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
817
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

18.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptomics and AI-driven approaches to the diagnosis and treatment of rheumatoid arthritis.

Frontiers in immunology·2026
Same author

Significance of miRNA Profile of Regulatory T Cells (Tregs) After Baricitinib Treatment in Rheumatoid Arthritis Patients.

European journal of immunology·2025
Same author

The role of calprotectin in giant cell arteritis - from pathophysiology to possible clinical applications.

Frontiers in immunology·2025
Same author

Beyond interferon gamma - decreased cellular response to COVID-19 vaccination booster in patients with autoimmune inflammatory rheumatic diseases.

Frontiers in immunology·2025
Same author

Thrombotic Markers in Plasma as Predictors of Response in Rheumatoid Arthritis Patients Treated with Baricitinib - Pilot Observation.

Archivum immunologiae et therapiae experimentalis·2025
Same author

Adipose-Derived Mesenchymal Stem Cells from Arthritis Patients: Differential Modulation of CD4⁺ T Cell Activation and Cytokine Production.

Medical science monitor : international medical journal of experimental and clinical research·2024

Related Experiment Video

Updated: Feb 19, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K

Targeting interferons as a strategy for systemic sclerosis treatment.

Marzena Ciechomska1, Urszula Skalska1

  • 1National Institute of Geriatrics Rheumatology and Rehabilitation, Warsaw, Poland.

Immunology Letters
|November 7, 2017
PubMed
Summary

Systemic Sclerosis (SSc) involves inflammation and fibrosis. Interferons (IFNs) contribute to SSc pathogenesis and may serve as biomarkers, suggesting IFN-blocking therapies could be effective treatments.

Keywords:
AnifrolumabAutoimmunityCytokinesFibrosisIFN signalingInterferonSystemic sclerosisVasculopathy

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.6K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.6K

Related Experiment Videos

Last Updated: Feb 19, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.6K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.6K

Area of Science:

  • Immunology
  • Rheumatology
  • Pathogenesis of Autoimmune Diseases

Background:

  • Systemic Sclerosis (SSc) is a severe autoimmune disorder marked by vasculopathy, inflammation, and fibrosis, often leading to organ damage and mortality.
  • Interferons (IFNs) are crucial immune cytokines implicated in SSc pathogenesis, with elevated levels in patients correlating with disease severity.
  • IFNs and IFN-inducible genes play a significant role in the development and progression of Systemic Sclerosis.

Purpose of the Study:

  • To review the current understanding of all Interferon (IFN) types and IFN-inducible genes in Systemic Sclerosis (SSc) pathogenesis.
  • To explore the potential of Interferons (IFNs) as biomarkers for SSc activity and progression.
  • To evaluate the therapeutic potential of blocking Interferon (IFN) pathways in SSc and related autoimmune conditions.

Main Methods:

  • Comprehensive literature review of scientific articles and clinical studies on Interferons (IFNs) and Systemic Sclerosis (SSc).
  • Analysis of existing data on IFN levels, IFN-inducible gene expression, and their correlation with SSc clinical parameters.
  • Synthesis of evidence supporting the role of IFNs in SSc pathogenesis and the rationale for therapeutic interventions.

Main Results:

  • Interferons (IFNs) are confirmed to be key players in the autoimmune processes, inflammation, and fibrosis characteristic of Systemic Sclerosis (SSc).
  • Elevated Interferon (IFN) levels in SSc patients are associated with clinical markers such as skin thickness and overall disease activity.
  • IFN-inducible genes are upregulated in SSc, contributing to the disease's fibrotic and inflammatory manifestations.

Conclusions:

  • Interferons (IFNs) are integral to Systemic Sclerosis (SSc) pathogenesis and show promise as reliable biomarkers for disease activity.
  • Targeting Interferon (IFN) signaling pathways represents a potentially effective therapeutic strategy for managing SSc.
  • IFN-blocking therapies warrant further investigation for their efficacy in treating Systemic Sclerosis (SSc) and other autoimmune diseases.